A systematic review of anti-cancer roles and mechanisms of kaempferol as a natural compound

Elham Amjad†, Babak Sokouti*† and Solmaz Asnaashari*†

Abstract

It has been shown in multiple experimental and biological investigations that kaempferol, an edible flavonoid generated from plants, may be used as an anti-cancer drug and has been shown to have anti-cancer properties. Many signaling pathways are altered in cancer cells, resulting in cell growth inhibition and death in various tumor types. Cancer is a multifaceted illness coordinated by multiple external and internal mechanisms. Natural extracts with the fewest side effects have piqued the attention of researchers in recent years, attempting to create cancer medicines based on them. An extensive array of natural product-derived anti-cancer agents have been examined to find a successful method. Numerous fruits and vegetables have high levels of naturally occurring flavonoid kaempferol, and its pharmacological and biological effects have been studied extensively. Certain forms of cancer are sensitive to kaempferol-mediated anti-cancer activity, although complete research is needed. We have endeavored to concentrate our review on controlling carcinogenic pathways by kaempferol in different malignancies. Aside from its extraordinary ability to modify cell processes, we have also discussed how kaempferol has the potential to be an effective therapy for numerous tumors.

Keywords: Anti-cancer, Natural compounds, Kaempferol, Mechanisms, Signaling pathways

Introduction

Cancer is an irregularity in the proliferation of various cells in different body tissues and is referred to as a group of diseases with an unmanageable growth and abnormal mechanism of cell division [1]. At the same time, there is always a balance between cell division, death, and differentiation [2]. The exact reasons for cancer are still unknown. Still, genetic and environmental factors such as ionizing radiations, viral infections, chemical and toxic substances, or excessive sunlight that disrupt cell function can cause abnormalities in the cell nucleus [3, 4]. The body’s defense immune response is insufficient to manage the condition [2].

Biology, environment, lifestyle, and healthcare organization are central to preventing cancer and other chronic diseases. However, all of these issues are limited by environmental factors such as economic context, agricultural dimensions, nutrition, pollution, social condition, and education of individuals that can make healthy behavioral choices impossible [5–7].

More than 200 types of cancer are known. Many factors can lead to abnormal cell growth and eventually cancer, but what is important is early detection of cancer, which raises hopes for the effectiveness of the treatment [8–12]. It is not uncommon to utilize a mix of the most prevalent cancer therapies (such as surgery or chemotherapy) to
treat the disease, depending on the patient’s natural state and the kind of cancer [13–15]. Due to the adverse effects and drug resistances of mentioned treatments, natural compounds have been considered in the prevention and treatment of cancers and also reducing the chemotherapies side effects [15–17]. The use of natural compounds in treating various diseases has been prevalent since ancient times. About 80% of people worldwide use these compounds and are widely dependent on them [18]. These structures target the tumor cells by regulating cell death pathways, including apoptosis and autophagy [19].

One of the most common flavonoid compounds in plants is a tetrahydroxyflavone from the flavonol family known as kaempferol (i.e., 3,4',5,7-tetrahydroxyflavone), as shown in Fig. 1, along with its potential analogous structures. It is found in many plants, particularly edible or medicinally important [20]. Previous epidemiological research shows kaempferol has been linked to various cardiovascular, cancer, inflammatory, neurodegenerative,

![Diagram of Flavonoid Compounds](image-url)
and obese diseases [21]. Researchers have well-described kaempferol’s chemopreventive and therapeutic activities in previous studies [15, 22]. In this research, we will conduct a comprehensive investigation and discussion to determine how kaempferol may be used to prevent and treat different cancer types.

**Pharmacokinetics of kaempferol**

The biological and pharmacological effects of flavonoid structures are related to their original characteristic mechanisms of action and the activity of their metabolites due to their widespread and rapid biotransformation [23, 24]. Due to the variety of the binding substituents, most natural flavonoid structures, such as kaempferol, are commonly presented and consumed as glycoside forms [20, 25]. Although the high polarity of the attached glycosyl groups to the aglycon reduces their absorption, previous studies have revealed that flavonoid glycosides absorption without hydrolysis is feasible [26]. The lipophilic nature of this structure leads to passive and facilitated diffusion absorption; however, scientific research demonstrated that it might also be absorbed as an active transport process [27, 28]. Conjugation enzymes metabolize kaempferol to glucuronides and sulfooconjugates in the small intestine. It can also be hydrolyzed by colon microflora and converted to simple phenolics (e.g., 4-hydroxyphenyl acetic acid, phloroglucinol, and 4-methyl phenol) to absorb or exert in feces.

Moreover, the absorbed part of kaempferol is metabolized into glucuronides and sulfoo-conjugates in the liver. Finally, the conjugated forms of kaempferol create phenolic chemicals in the colon, and kaempferol and its glycoside derivatives are eliminated in the urine [20, 28]. Earlier studies demonstrated that 3-glucuronide conjugate of kaempferol was the main detected component in plasma and urine. Likewise, the urine excretion of consumed kaemferol was approximately 1.9% to 2.5%. [29, 30]. Following oral ingestion of kaempferol, many human investigations have shown that the concentration of the compound in plasma is confined to nanomolar levels. For example, in a 2002 study by Radtke, the plasma concentration of kaempferol was reported to be 10.7 nM, while the intake amount was 4.7 mg/day [31]. Another research found that ingesting 27 mg of kaempferol in the form of daily tea resulted in a plasma concentration of 52 nM (15 g/L), which was attained by consuming 52 nM (15 g/L) of kaempferol [30]. A plasma concentration of 57.86 nM of kaempferol was measured in a dietary intervention study on 92 healthy students (mean age: 24.16 years; mean BMI: 21.31 kg/m2) [32].

**Anti-cancer activities of kaempferol in literature cancer types**

A thorough review of the Scopus database was carried out on different types of cancer using “kaempferol” as their treatments, which will be described as follows.

**Bladder cancer**

According to the GLOBOCAN latest report, bladder cancer considers 3% of diagnoses of global cancer and mainly occurs in developed countries [33].

Urinary tract carcinoma is the most frequent urinary system cancer [34]; Xie et al. demonstrated kaempferol’s preventative and therapeutic benefits from human bladder cancer with EJ cells. They reported significant anti-proliferative and anti-migration activities of this natural flavonol. The apoptotic mechanism activated by kaempferol is connected to the PTEN tumor suppressor gene through the PI3K/Akt signaling pathway [35]. In the other study, the assessment of MTT assay on two different bladder cancer cell lines (5637 and T24 cells) demonstrated that kaempferol increased cell cytotoxicity. Still, the analysis of flow cytometry, DNA ladder, and TUNEL assays resulted in significant kaempferol-induced apoptosis and cell cycle arrest. In vivo investigations (subcutaneous xenografted mouse models) supported these in vitro findings, with kaempferol-treated animals showing less cancer formation, whereas apoptotic markers are elevated. The research revealed that kaempferol might suppress cell growth by significantly downregulating the c-Met/p38 signaling pathway [36]. Kaemferol altered DNA methylation by creating 103 gene-specific differential DNA methylation locations (dDMPs), as was reported in a cell line research (using 5637 and T24 cells) and a 31-day in vivo investigation in nude mice with bladder cancer distress. The study concluded that kaempferol could promote the DNMT3B degradation through the ubiquitin–proteasome pathway and introduced as a novel DNMT3B inhibitor [37]. Wu and colleagues discussed the radical scavenging activity of kaempferol, its function in stimulating antioxidant enzymes, controlling ROS formation, and the anti-hemolytic effects of lipid peroxidation. Their study showed that kaempferol was a potent inhibitor in bladder cancer with high safety on normal cells. Besides, it suppressed the phosphorylation of AKT, CyclinD1, CDK4, Bid, Mcl-1, and Bcl-xL, while boosting the expression of p-BRCA1, ATM, p53, p21, and p38, as well as Bax and Bid. It also promoted apoptosis and S phase arrest in EJ bladder cancer cells while decreasing proliferation [34].
Bone cancer
Primary bone cancers are the most severe type of bone cancers, consisting of about 0.2% of all worldwide malignancies derived from primitive mesenchymal cells involving several subtypes of osteosarcoma chondrosarcoma Ewing sarcoma [38]. Previous research on osteosarcoma cells showed that kaempferol might increase the expression of Box protein and decrease Bcl-2 protein, decrease mitochondrial membrane potential and increase caspase-3, -7, and -9 activities in the U-2 OS cell line. A rise in AIF protein levels was also observed, indicating that apoptosis was induced through a caspase-independent mitochondrial mechanism. The endoplasmic reticulum stress pathways are the other mechanism induced by kaempferol in the human osteosarcoma cell line. In a study, the in vivo evaluation confirmed the anti-tumor effects of this bioflavonoid in mice models [39]. In another research, kaempferol inhibited cell metastasis in U-2 OS cells by inhibiting various signaling pathways (e.g., ERK, AP-1, JNK, and p38) [40]. When osteoblasts stopped producing osteoclastogenic cytokines and osteoclast precursor cells stop differentiating, kaempferol had an anti-osteoclastogenic impact on bone. It is due to antagonizing the TNF receptor family action on bone cells [41].

Breast cancer
Female breast cancer accounts for 11.7% of all cases and 6.9% of cancer deaths globally [42]. There are several studies on kaempferol’s effects and possible mechanisms on breast cancer. In 2004, Hung published an article that showed the significant efficacy of kaempferol on the impairment of the estrogen receptor-α and blocking the estradiol-induced cell proliferation, while estrogen receptor (ER)-negative breast cancer cells didn't show growth resistance toward the kaempferol [43]. In some in vitro and in vivo studies, kaempferol is a phytoestrogen that inhibits triclosan and exhibits estrogen's effects on the growth of breast cancer cells [44]. Cyclin D1, cyclin E, and cathepsin D expressions were upregulated in cells treated with triclosan, whereas p21 and Bax expressions were downregulated, and these gene expressions were blocked by kaempferol. This compound also inhibited 17β-estradiol and triclosan-induced expression of pIRS-1, pAkt, and pMEK1/2 [44]. Similar results to in vitro studies on tumor growth inhibition were observed in the in vivo xenografted mouse model [44]. In addition to ER-agonist, this phytoconstituent was known as AHR-antagonist (aryl hydrocarbon receptor), which was related to the inhibition activity on transcription of AHR in ER-α-negative breast cancer cell lines independent of ER-α expression [45]. Generally, the biphasic responses (via ER-dependent and ER-independent pathways) of kaempferol on.

Estrogen receptors were reported, which explained the role of this compound in regulating the body's estrogenic activity and its valuable potency in inhibiting estrogen imbalance diseases [46]. As an ERK activation inducer, kaempferol may also activate MEK1 and ELK1 (a sub-strate of the ERK). Another study has demonstrated that they effectively reduce breast cancer cell viability [47]. The suggested chemoprotective mechanism of kaempferol can result in toxicity and proliferation arrest due to the downregulation of glucose transporter 1 (GLUT1) gene expression and inhibition of cellular glucose uptake in cancer cell lines. Furthermore, this flavonol structure could inhibit the cancer cell's monocyte cell surface receptor (MCT1)-mediated lactate reuptake and destroy [48]. Downregulation of the matrix metalloproteinase-9 (MMP) expression and activity was the other process in breast cancer invasion treated with kaempferol using the MDA-MB-231 cell line [49]. This component inhibited AP-1, PMA-induced MMP-9 production, PKC-δ translocation, and MAPK signaling [49]. Furthermore, treating MCF-7 cells with kaempferol influenced the aryl hydrocarbon receptor in inhibiting CYP1A1 transcription, and CAT transcription was likewise suppressed by kaempferol. Moreover, kaempferol totally reduced the induction of 2,3,7,8-tetrachlorodibenzo-p-dioxin in band shift [50].

Cancer stem cell markers, such as Oct-4, Nanog, ABCB1, and ALDH1A1, were significantly reduced in MCF-7 cells treated with kaempferol and docetaxel. This study reported kaempferol as a more effective anti-cancer agent than docetaxel [51]. Kaempferol was a suppressor of primary tumor growth and lung cancer metastases in a mouse breast tumor model [52]. It reduced the expression of H3-cit (citrullinated histone H3) as a neutrophil extracellular traps biomarker (NETs), involved in NADPH/ROS-NETs signaling, and reduced tumor metastasis by inhibiting the ROS-PAD4 pathway [52]. Kaempferol could also suppress the proliferation of triple-negative breast cancer, contribute to the G2/M arrest induction, induce apoptosis and DNA damage, increase the expression of γ-H2AX and cleave the caspase-9, caspase-3, and p-ATM in comparison with the control group [53].

According to previous studies, various isolated kaempferol derivatives from the plant species, such as prenylated kaempferol and kaempferol-3-O-rhamnside, also have noticeable inhibitory effects on breast cancer cells [54, 55]. Activating the caspase cascade signaling system could suppress breast cancer cells (MCF-7) growth and promote the apoptotic process in breast cancer cells [55]. Moreover, according to a recent study,
a conjugate form of 1-deoxynojirimycin and kaempferol linked by an undecane chain revealed significant lipophilicity, anti-proliferative, and anti-α-glucosidase activities. The new derivative showed downregulation of the expression of COX-2, inhibited migration, decreased intracellular ROS and calcium cation levels, decreased Bcl-2 expression, and increased Bax expression in MCF-7 cells [56].

The other factors influencing the kaempferol mechanism of action in breast cancer are its pharmaceutical formulation and particle size, considered in two previous studies. The gold nanoparticles (AuNPs) and nanostructured lipid carriers (NLCs) of kaempferol are suggested as powerful drug delivery techniques in the management of breast cancer cells through the antioxidant, anti-proliferative, and antiangiogenic properties [57, 58].

Cervical cancer

Cervical cancer was the fourth most often diagnosed and the fourth major cause of cancer mortality in women globally in 2020, with over 604,000 new cases and 342,000 fatalities [42]. Kaempferol impacted the glucose uptake and inhibited mitochondrial respiration in HeLa cells (derived from cervical cancer cells). In addition, HeLa cells activated autophagy as a survival response to this bioflavonoid. This study revealed that autophagy was related to early activation of the AMPK/mTOR-mediated pathway [59]. Apoptosis and cell cycle arrest was observed in HeLa cells when Kaempferol-7-O-b-D-glucoside, an extraction of Similax china L. rhizome, was tested. This glycoside also reduced NF-κB nuclear translocation, increased Bax protein, and decreased Bcl-2, indicating a mitochondrial pathway in apoptosis [60].

Colon cancer

The GLOBOCAN 2020 research showed that rates of colon cancer are much higher in transitioned countries than in transitional countries. However, there is no significant difference in mortality rates because of the greater mortality in transitioning nations [42]. A previous study on the kaempferol effects on three colon cancer cell lines (MSU-2, HCT116, and KNC) with diverse expressed gap junction genes and function profiles concluded the possibility of anti-cancer properties with different functions [61]. The results of evaluations on KNC cells (it is expressed in connexin43 mRNA but lacked in gap junctional intercellular communication (GJIC) and Cx43 expression) indicated the ability of this flavonol structure on the induction effect of alkaline phosphatase (ALPase), reduction on Stat3, restoration of connexin43 protein (Cx43) phosphorylation, and functional GJIC. The Jak/Stat3 signaling pathway suppression was suggested as the important mechanism in the cells mentioned above.

According to the results of this study among three different cell lines (MSU-2, HCT116, and KNC), kaempferol is considered a cytostatic component for only KNC cells [61]. According to Lee et al. studies, kaempferol made a series of molecular changes in the growth inhibition and HT-29 colon cancer cell line apoptotic function. In addition to a decrease in Bcl-xL and intact Bid, as well as an increase in Bik, Bad mitochondrial proteins, and the activation and cleavage of caspase-9, apoptosis function was caused by changes in the Bcl-2 family protein levels and localization (such as the reduction of Bcl-xL and intact Bid, as well as an increase in the Bik and mitochondrial Bad proteins).

Furthermore, the activation of caspase-8, the cleavage of caspase-3 and Bid, and the decrease of phospho-Akt and Akt activity by kaempferol led to Bad mitochondrial translocation [62]. Based on Budisan et al’s studies, cell viability impairment, cell proliferation inhibition, apoptosis induction and autophagy, modifications in coding, and noncoding expression of genes have occurred in RKO and HCT-116 colon cancer Cell Lines treated with kaempferol [63]. Also, fewer cells in the G1 phase, but more in the G2 phase, were seen after kaempferol treatment [63].

The activation of death receptor 5 (DR5) by kaempferol increased the sensitivity of colon cancer cells to TRAIL-induced apoptosis in studies including medication combinations. In contrast, combining these two components didn’t have significant cytotoxic effects on normal cells. Subsequently, the variety of kaempferol and TRAIL was introduced as a beneficial approach to cancer therapies [64]. Similar outcomes were observed in the kaempferol and 5-fluorouracil combination in HcT-8 and HcT-116 cell lines. The results indicated the synergistic effects of this bioflavonoid and 5-fluorouracil on cell viability, proliferation reduction, and apoptosis induction [65].

The molecular evaluation showed the upregulation of the Bax expression levels, downregulation of Bcl-2 and TS expression levels, and inhibition of the PI3K/Akt pathway [65]. A recent study reported that the combination of fluoxetine and kaempferol improved several biological properties such as the antioxidant, anti-inflammatory, and anti-proliferative effects with developed apoptotic activity and could exhibit a more potent chemopreventive effect against 2-dimethylhydrazine-induced preneoplastic lesion in rat colon than using fluoxetine alone [66]. Eventually, a recent experiment demonstrated that the combination of doxorubicin (DOX) and kaempferol was more efficient in induction of apoptosis and cytotoxic effect against HT-29 colon cancer cell line in comparison with each drug alone; also combined drug nanoformulations (polyethylene glycolated gold nanoparticles of doxorubicin-kaempferol) revealed a critical decreasing in the
volume of colon tumor on the in vivo model without any severe side effects [67].

Endometrial cancer
Endometrial cancer is the sixth most frequent malignancy in women and one of the most common malignancies in gynecology [68]. Nulliparity and metabolic abnormalities such as obesity have been linked to an increased incidence of this condition, which is one of the estrogen-dependent diseases [69]. Kaempferol inhibited the viability of Ishikawa and HEC-265 cells in previous research (estrogen receptor-positive, human endometrial adenocarcinoma cell line). At concentrations as low as 80 µg per milliliter, kaempferol inhibits the development of Ishikawa and HEC-265 cells. It induced the G2/M phase and suppressed the G1 phase. According to the results, this bioflavonoid structure led to apoptotic cell death in Ishikawa and HEC-265 cancer cells by decreasing endoplasmic reticulum (ER), survivin, and Bcl-2 levels and increasing p53 and PARP expression [69]. HEC108 cell line and growth of HEC180 were unaffected by kaempferol in the same research [69]. Using the human endometrial cancer cell line MFE-280 as a model, researchers found that inhibiting mTOR/Pi3K/Akt signaling led to triggering apoptosis and halting cell cycle progression with substantial anti-cancer effects [70].

Gastric cancer
There are around 1.1 million new cases of this disease each year, and 768,793 deaths from it are reported in the GLOBOCAN database, making it one of the most common diseases in the world. Nulliparity and metabolic abnormalities such as obesity have been linked to an increased incidence of this condition, which is one of the estrogen-dependent diseases [69]. Kaempferol inhibited the viability of Ishikawa and HEC-265 cells in previous research (estrogen receptor-positive, human endometrial adenocarcinoma cell line). At concentrations as low as 80 µg per milliliter, kaempferol inhibits the development of Ishikawa and HEC-265 cells. It induced the G2/M phase and suppressed the G1 phase. According to the results, this bioflavonoid structure led to apoptotic cell death in Ishikawa and HEC-265 cancer cells by decreasing endoplasmic reticulum (ER), survivin, and Bcl-2 levels and increasing p53 and PARP expression [69]. HEC108 cell line and growth of HEC180 were unaffected by kaempferol in the same research [69]. Using the human endometrial cancer cell line MFE-280 as a model, researchers found that inhibiting mTOR/Pi3K/Akt signaling led to triggering apoptosis and halting cell cycle progression with substantial anti-cancer effects [70].

Liver cancer
It is estimated that the world’s most common primary cancer diagnosis and the third leading cause of cancer-related death will both be liver cancers in 2020 [42]. Additionally, there were more than 900,000 new cases and 800,000 deaths, with males having 2–3 times the
prevalence and fatality rates [42]. A review of the previous research has shown that kaempferol affects liver cancer cells by altering multiple molecular mechanisms and pathways in cancer progression. For example, Mylonis et al. revealed the influential role of kaempferol in inhibiting the viability of hepato tumor (Huh7) cancer cells, HIF-1, and MAPK in hypoxic conditions [80]. According to an in vitro study, kaempferol could mediate the levels of nucleic acids, membrane-bound ATPase (Na+/K+ ATPase, Mg2+ ATPase, and Ca2+ ATPase), mitochondrial TCA cycle, and carbohydrate metabolizing enzymes (hexokinase, phosphogluco-isomerase, aldolase, glucose-6-phosphatase, and fructose-1,6-diphosphatase) in aflatoxin B1 (AFB1) induced hepatocellular carcinoma. It was introduced as a potent anti-carcinogenic factor [81]. In another study, kaempferol acted as an anti-inflammatory agent. Its ability was proven to abolish the down-regulatory action of TNF-α on liver-X-receptor alpha (LXR-α) in a dose-dependent manner [82].

Moreover, autophagy induction via upregulation of AMPK, downregulation of Akt and mTOR signaling pathways, and the induction of G2/M arrest through CDK1/cyclin B downregulation were observed in kaempferol-treated SK-HEP-1 cancer cells [83]. The assessment of different concentrations of kaempferol on ABCA1, mRNA expression levels in TNF-α stimulated HepG2 cell line demonstrated that although in the TNF-α-simulated inflammatory condition, kaempferol couldn’t reduce the expression of ABCA1 rising back to untreated levels; high dose of this compound could only upregulated the ABCA1 mRNA expression considerably, which showed a positive relevance between ABCA1 and kaempferol. It was suggested that this bioflavonoid could be used as a suitable preventative agent in Tangier disease [84]. One of the main mechanisms proposed by Guo et al. in their in vitro investigation of HepG2 cells was the ER stress CHOP pathway, which increased the production of protein and mRNA of ER stress indicators [85]. The flavonoid structure was shown to promote apoptosis in hepatocytes in the rat model of hepatocellular carcinoma through the mitochondrial-dependent pathway by targeting upstream activities such as the enhancement of ROS formation, MMP downregulation, and the increasing of the caspase-3 activity in the cytosol [86]. Several pieces of literature described the protective effects of kaempferol on the liver against various oxidative stresses [87, 88]. By activating mitochondria and inhibiting the signaling pathways of PI3K/mTOR/MMP, kaempferol limits liver cancer cell proliferation and migration. And results showed that kaempferol didn’t have any significant toxicity on normal cells [89]. This report also demonstrated a synergistic influence and more significant inhibitory effects of proliferation, migration, and invasion on liver cancer in combined treatment with doxorubicin and kaempferol. It was suggested that this bioflavonoid could interrupt cancer cell survival signaling pathways and may compensate for the shortcomings of monotherapies. Furthermore, the multi-targeting activity of kaempferol can reduce drug resistance during treatment [89].

Following Shakya et al’s report, kaempferol protected the liver against alcohol- and thermally oxidized polyunsaturated fatty acid-induced oxidative stress [88]. Moreover, a recent study anticipated that kaempferol and kaempferide (kaempferol 4’-methyl ether) possessed significant effects on Nonalcoholic fatty liver disease (NAFLD) prevention and treatment, which might cause some necroinflammatory responses such as nonalcoholic steatohepatitis and consequently cancer [87, 90]. The induced molecular mechanisms of these two flavonol structures were reduced lipogenesis-related protein expression (e.g., SREBP1, FAS, and SCD-1). Moreover, they have decreased the expression of PPARγ, C/EBPβ, and two adipogenic transcription factors, HO-1 and Nrf2 [87]. Moreover, the molecular docking approach presented that the binding of kaempferol and kaempferid to SCD-1 could introduce an essential regulator in lipid metabolism [87]. Along with in vitro and in vivo experiments, in silico evaluations also confirmed the anti-liver cancer potential of kaempferol. The well-binding affinities to the receptor FKBP12-rapamycin binding domain and AKT serine/threonine-protein kinase concluded the improved efficacy in inhibiting mTORC1 compared with everolimus as a standard drug [91].

The studies above and several previous data show that kaempferol’s different synthetic and natural derivatives also presented significant cancer-fighting effects against hepatocarcinoma cells [54, 92].

Lung cancer

In 2020, greater and less than 2.0 million new cases and fatalities were due to lung cancer, respectively [42]. Cancer experts think that non-small cell lung cancer (NSCLC) is responsible for more than 11% of the worldwide cancer burden and more than 18% of all cancer fatalities [93]. The authors found that kaempferol significantly decreased in vivo lung metastasis using a realistic and uncomplicated B16F10 melanoma metastatic model. These inhibitory effects decreased MMP-9 synthesis and activity by reducing the MAPK and PKC signaling pathways. A549 cells die due to kaempferol’s ability to inhibit the PI3K/AKT and ERK pathways. According to the results [94, 95], kaempferol suppressed A549 cells via activating the apoptosis pathway. A different test in NSCLC cells uses Nrf2 reporter luciferase as a biomarker (A549 and NCI-H460). Nrf2 siRNA decreased NQO1 protein levels in A549 and NCI-H460 cells [96]. In
comparison to normal lung epithelial cells, NSCLC cells (A549 and NC1H460) express more significant amounts of Nrf2, as well as its downstream proteins NQO1 and HO1 (L132) [97]. At zero and 24 h following treatment with K-AuNCs, the researchers evaluated if kaempferol-conjugated AuNCs showed equivalent anti-migratory effects on A549 lung cancer cells. Kaempferol, toxic to lung cancer cells but not HK-2 human kidney normal cells, can be efficiently conjugated to AuNCs. It has been shown that K-AuNCs govern the development of A549 cells [98]. Pretreatment of A549 cells with kaempferol significantly decreased the toxicity of TGF-1. Through dephosphorylation of Smad3 at the Thr179 site in A549 lung cancer cells, kaempferol inhibits the EMT, migration, and MMP-2 activation induced by TGF-1 in these cancer cells. Kaempferol’s ability to inhibit cancer cell development has been linked to estrogen-related receptors (ERRs) and its activity [99]. Finally, the fact that A549 lung cancer cells were resistant to TGF-1-induced EMT, migration, and activation of MMP-2 suggests that kaempferol’s antimetastatic effect may target essential components of numerous signaling pathways implicated in tumor metastasis. In addition, in A549 cells, kaempferol-induced apoptosis seems to need MEK-MAPK activation, which acts before caspase-7. For the A549 lung cancer cell line, kaempferol is toxic to the cells. Kaempferol enhances the MEK/MAPK, affects the Bcl-2 proteins, and inhibits the phosphorylation of Akt1 to activate apoptosis [100]. By cleaving PARP and caspase-7, the MEK1/2 inhibitor prevents kaempferol-induced apoptosis. A549 cell death requires MEK-MAPK activation, which occurs before caspase activation, according to the literature findings [94].

Nervous system cancer
According to the 2020 GLOBOCAN report, brain and nervous system cancer comprised more than 308,000 and 251,000 new cases and deaths, respectively [42]. It has been shown that the combination of kaempferol and TRAIL might be an essential strategy for treating glioma by suppressing survivin protein degradation [101]. Apoptosis was reduced when survivin was overexpressed in the cell. Kaempferol was also responsible for downregulating phosphorylated Akt and reducing the quantity of survivin protein to stop survivin [101]. It was discovered in this study that TRAIL and kaempferol were able to imitate caspase-8 cleavage while also having an anti-apoptotic effect that was not inhibited by survivin, which has been demonstrated in earlier research not to affect caspase-8 activation. As well as this, the apoptosis inhibitory Bcl-2, Bcl-xL, and Mcl-1 family members were all reduced in concentration by kaempferol [101]. Kaempferol was also shown to elicit caspase-dependent pathways, including the downregulation of XIAP and survivin, which ERK and Akt regulate in the other investigation on A172 human glioma cells [102]. Kaempferol was also shown to have neuroprotective properties against 4-hydroxynonenal-induced apoptosis in PC12 cells. This natural flavonoid prevented the 4-hydroxynonenal-induced apoptosis, linked to nuclear condensation, Bcl-2 downregulation, and proapoptotic caspase-3 activation. Additionally, it prevented phosphorylation of c-JNK in response to 4-hydroxynonenal, which was bound to p47phox, and inhibited NADPH oxidase activity in response to 4-hydroxynonenal (NOX). Results indicated that kaempferol might be a preventative agent against NADPH oxidase-mediated neurodegenerative disorders [103].

In 2018, an investigation on IMR32 and Neuro2A cells (human and mouse neuroblastoma cell lines), showed this flavonol structure induced neuroblastoma differentiation, decreased cell viability, promoted apoptosis, modulated the IRE1α (inositol-requiring enzyme one alpha) expression, and activated the IRE1α endoribonuclease [104].

Ovarian cancer
As mentioned in the GLOBOCAN report, ovarian cancer has been considered a severe women malignancy, with 313,959 new cases in 2020 worldwide [42]. Based on the previous studies on OVCAR-3 (mutant p53), wild-type p53 of A2780/CP70 cells, anti-angiogenesis, and the significant inhibitory effects of kaempferol on VEGF (Vascular endothelial growth factor) gene expression via both Akt/HIF and ESRRA pathways were described [105]. The other study confirmed tumor anti-angiogenesis effects of kaempferol and added the induction effects of this flavonoid compound on G2/M cell cycle arrest through the Chk2/Cdc25C/Cdc2 and Chk2/p21/Cdc2 pathways in A2780/CP70 ovarian cancer cells [106]. The researchers described that kaempferol could increase the DR5 and Fas expression level and stimulate the extrinsic apoptosis pathway through the death receptors/FADD/Caspase-8 and Chk2 was not a responsible factor for the apoptosis induction and upregulation of p53 by kaempferol [106]. Kaempferol also displayed anti-proliferative properties on several human ovarian cancer cells (Caov-3, TOV-112D, SKOV-3, and OVCAR-3) by triggering autophagy and apoptosis G0/G1 cell cycle arrest and inhibition of MEK/ERK and STAT3 pathways [107]. In a recent study on A2780 cells, kaempferol effects increased cell apoptosis and decreased viability and proliferation. Furthermore, rising GRP78, PERK, ATF6, IRE-1, LC3II, beclin 1, and caspase-4 levels stimulated the cytotoxic endoplasmic reticulum/autophagy mechanism, which was related to enhancing intracellular calcium cation levels. Cancer
cells were made more sensitive to cisplatin by kaempferol, which did so via lowering the protein p-Akt in the cells [108]. Various studies have suggested using kaempferol combined with cisplatin to control the drug resistance problem in ovarian cancer [106, 108]. Earlier studies have also shown the synergistic effects of kaempferol and cisplatin inhibiting ABCG6 and cMyc gene transcription in ovarian cancer cells [109]. It should be noted that nano-formulations of kaempferol had a more influential role in reducing the survival of ovarian cancer cells than kaempferol alone [110].

**Pancreatic cancer**

Affecting both men and women throughout the world, pancreatic cancer has a bleak outlook, making it one of the most dangerous and lethal tumors to develop [42]. Scientific research on three human pancreatic cancer cell lines (MiaPaCa-2, Panc-1, and SNU-213 cells) presented the anti-cancer effect of kaempferol via viability reduction and apoptosis increasing in a dose-dependent manner [111]. This study introduced kaempferol as an anti-viable, antioxidant, anti-migration agent with no toxicity in low doses. It could mediate the anti-cancer activities against pancreatic cancer by blocking EGFR-related Src, ERK1/2, and AKT signaling pathways. Two glucoside derivatives of kaempferol (kaempferol-3-O-glucoside and kaempferol-4′-O-glucoside) didn’t show any anti-cancer effects in the mentioned study [111].

Moreover, a recent study showed that kaempferol could successfully suppress pancreatic cancer in vivo and in vitro models. Akt/mTOR signaling activation might diminish the TGM2 mRNA and protein levels and ROS generation. Raising the expression of tissues transglutaminase is the cause of downregulation of ROS production, inhibition of related signaling pathways, and poor prognosis in pancreatic ductal adenocarcinoma [112].

**Prostate cancer**

Prostate cancer is anticipated to be the second most common cancer in men and the fifth leading cause of cancer deaths globally by 2020, with an estimated 1.5 million new cases and 0.4 million fatalities [42]. As mentioned above, even though the inhibition of cancer cell growth and apoptosis induction were the main mechanisms of kaempferol, promoting the body’s immunity also plays an essential role in fighting against various types of cancer. As an example, an investigation of the effects of kaempferol on the production of granulocyte-macrophage colony-stimulating factor (GM-CSF) in prostate cancer cells (PC-3) demonstrated the increasing of GM-CSF release by PC-3 kaempferol -treated cells without any disturbance on the mRNA levels could improve the activation of the antigen-presenting dendritic cells and the host immune system and consequently could develop the tumoricidal immune response. This natural flavonol stimulated the production of GM-CSF by activating the PLC, PKC, and MEK1/2 cascade [22]. The other literature study represented the apoptosis stimulating role of kaempferol in a dose-depend manner in the presence of dihydrotestosterone on LNCaP cells (androgen-sensitive human prostate adenocarcinoma cells). Moreover, it could inhibit the activities of dihydrotestosterone-induced androgen receptors and decrease the downstream targets of androgen receptors (e.g., PSA, TPRSS2, and TMEPA1) and PSA protein levels, and also inhibit androgen receptor protein expression and nuclear accumulation. Eventually, kaempferol could suppress the vasculogenic mimicry formation and invasive potency in a dose-dependent manner [113]. Other research has shown that it may have an anti-proliferative impact depending on how much kaempferol-3-O-rhamnoside is applied to LNCaP cells. For this reason, in LNCaP cells, it caused an increase in the expression of the enzymes caspase-8, -9, -3, and ADP-ribose polymerase[114].

**Skin cancer**

Skin cancer, which develops when skin cells grow abnormally and unchecked, is one kind of cancer that may spread throughout the body. This malignancy is divided into two main groups keratinocyte cancers known as non-melanoma and melanoma [115]. According to the last GLOBOCAN data, over one million new cases with 63,731 death of non-melanoma (excluding basal cell carcinoma) and 324,635 new cases with 57,043 death of melanoma were reported in 2020 [42]. Based on the previous study of kaempferol-treated HaCaT cells, the results demonstrated 147 transcripts (including 18 upregulation and 124 downregulation) in cDNA microarray analysis that caused significant expression changes [116]. The results showed the role of kaempferol on the simulation of PPAR transcriptional activity in the HaCaT cell line, which transiently transfected with the PPRE-tk-Luc reporter gene, and suggested that its action mode could be mediated by PPAR pathways [116].

Moreover, recently published literature reported *Prunus cerasus* L, extract (sour cherry) as a source of essential polyphenols such as kaempferol, quercetin, and chlorogenic acid during apoptotic cell death of HaCaT cell line exposed to airborne particles with a diameter less than 10 µm. Cell viability decreased, reactive oxygen species were inhibited, and apoptosis-related gene expression (e.g., Bax, Bcl-2, and caspase-3) was inhibited due to the activation of transcription factor NF-kB [117]. The other experiment revealed that kaempferol significantly inhibited EGF-induced neoplastic transformation in
and QBC939 cells’ proliferation and colony formation. This natural polyphenol inhibited HCCC-9810 cell migration and apoptosis in the presence of melanoma malignancy, as well as downregulating the levels of mTOR, phosphorylated (p) mTOR, PI3K, and Akt proteins [120].

Others

We summarized their information in this section because of fewer published experimental data for kaempferol effects on the other types of cancer cells. A study performed on the effects of kaempferol on head and neck squamous cell carcinomas revealed that this compound could inhibit the rate of oxygen consumption and reduce the content of intracellular ATP in tumor cells, which could induce anti-proliferative activities and tumor cells apoptosis and also could inhibit the capacity of migration. Furthermore, the results showed that combining this bioflavonoid and cisplatin could improve cisplatin resistance limitation in mentioned cancer cells [121].

On esophageal squamous cell carcinoma, kaempferol showed significant inhibitory effects on tumor cell proliferation and clone creation in an experiment for colony formation and cell colony formation. Kaempferol induced the G0/G1 phase arrest, changes in protein expression involved in cell cycle regulation, and inhibits tumor glycolysis in tumor cells. The epidermal growth factor receptor (EGFR) signaling pathway was reported as the possible mechanism for described function [122].

Apoptosis was activated, and cell cycle arrest was seen in 786-O and 769-P cells treated with kaempferol discovered by Song et al. They found that this bioflavonoid inhibited the EGFR/p38 MAPK signaling pathways, increased p21, decreased cyclin B1, stimulated PARP cleavages, induced apoptosis, and inhibited cell proliferation in human renal cell carcinoma (RCC) cells [123].

Kaempferol also reduced MMP production by inhibiting NF-kB and AP-1 activation in the HT1080 (human fibrosarcoma) cell line, which was associated with a substantial decrease of IkBa and JNK phosphorylation that was driven by phorbol-12-myristate-13-acetate [124]. These results demonstrated the chemopreventive effects of kaempferol in controlling the inflammation risk, tumor invasion, and metastasis involving MMP-9 [124].

Also, in vitro and in vivo studies revealed that kaempferol suppressed cholangiocarcinoma development and metastasis [125]. According to the in vitro experiments, this natural polyphenol inhibited HCCC-9810 and QBC939 cells’ proliferation and colony formation while inhibiting their migration and invasion capabilities. It was found that kaempferol decreased Bcl-2 expression and elevated Bax, Casp, cleaved-caspase-3, -8, -9, and PARP expressions. Furthermore, the phosphorylated AKT, TIMP2, and MMP2 were downregulated by kaempferol treatment [125]. The lung metastasis model saw fewer metastatic foci and lighter mice [125]. Moreover, decreasing the amount of Ki-67-positive cells was reported as a kaempferol effect [125].

According to previous research on retinoblastoma SO-RB50 cells, kaempferol affected the ERR-α. The Wnt/β-catenin signaling pathway stopped cells from making more copies of themselves and spreading. This report demonstrated the occurrence of G2/M arrest and apoptosis in the SO-RB50 cell line [126].

The extrinsic mechanism of apoptosis was used to show that the kaempferol derivative known as 3-O-b-isorhamninoside, isolated from Rhamnus alaternus L. leaves, caused apoptosis in human lymphoblastoid cells. The obtained results represented that the induced apoptosis of the mentioned glycoside of kaempferol was related to the stimulation of caspase-3 and PARP cleavage [127].

A previous in vitro study indicated that kaempferol and its glycoside (kaempferol-7-O-rhamnoside) inhibited PD-1/PD-L1 interaction, closely related to the T cell functions impairment and escape cancer cells from the immune surveillance [128]. In addition, decreasing the ERR-regulated target gene expression, such as reducing TFAM, Mfn2, Mn-SOD, and Cu/Zn-SOD gene expression and antagonizing the EER-α and -γ were related to the kaempferol effects on inhibiting mitochondrial biogenesis and cancer cells development [129].

The combined action of kaempferol with other chemicals

Previous research suggests that coordinating flavonoids with transition metal ions may increase the anti-cancer activity of flavonoids. According to the results of an MTT test, kaempferol-Zn was in a better position than free kaempferol to inhibit the growth of cancer cells and reduce their viability. These findings provided sufficient evidence to support the hypothesis that kaempferol-Zn has the potential to trigger apoptosis in EC9706 cells. Consequently, the mitochondria were further damaged by kaempferol-Zn, which led to cell death [129]. Colon cancer cells were treated with a PEGylated AuNPs-DOX@Kaempferol drug delivery system. This system relied on chemically modified PEGylated AuNPs and electrostatic hydrogen-bonding interactions. As the pH became more acidic, the DOX and kaempferol molecules were freed from their critical interactions, and medications could also be released at intracellular locations. It
| Cancer types   | Treatment | Study       | Cell Line          | Sample                                                                 | Dosage                  | Treatment Period | Mechanisms/Pathway                                                                 | Ref  |
|---------------|-----------|-------------|--------------------|------------------------------------------------------------------------|-------------------------|------------------|---------------------------------------------------------------------------------|------|
| Bladder cancer| Kaempferol| In vitro    | EJ                 | –                                                                      | 20–160 µM               | 24 and 48 h       | Activation of Caspase-3 c-Met/p38 signaling pathway                              | [35] |
|               | Kaempferol| In vitro    | 5637 and T24       | 6 to 8-week-old athymic BALB/cnu/nu male mice (subcutaneous xenografted mouse models) | In vitro: 50–150 µM, In vivo: 50–150 mg/kg | 48 h Intraperitoneal injection, daily, for four weeks | Ubiquitin–proteasome pathway                                                   | [36] |
|               | Kaempferol| In vitro    | 5637 and T24       | 5-week-old BALB/c nude mice (nude mice bearing tumor xenografts)       | In vitro: 40 µM, In vivo: 150 mg/kg | 24 and 48 h Intraperitoneal injection, daily, 31 days | Ubiquitin–proteasome pathway                                                   | [37] |
| Bone cancer   | Kaempferol| In vitro    | U-2 OS, HOB, 143B cells | BALB/cnu/nu mice (8 weeks old)                                         | In vitro: 25–200 µM, In vivo: 25 or 50 mg/kg | 24 h Oral administration, daily, 40 days | Endoplasmic reticulum stress pathway and mitochondrial signaling pathway        | [38] |
|               | Kaempferol| In vitro    | U-2 OS             | –                                                                      | 25–100 µM               | 48 h              | Blocking MAPKs and AP-1 signaling pathways                                      | [39] |
| Breast cancer | Kaempferol| In vitro    | ER-positive (MCF-7, T47D, and ZR-75) and ER-negative (MDA231) | –                                                                      | 17.5–70 µM             | 24 and 48 h         | Reduction in the expression of both IRS-1 and cyclin D1                        | [40] |
|               | Kaempferol| In vitro    | T47D, BT549 and MDA-MB-231 | –                                                                      | 10 µM                   | 24 h              | Inhibition of AHR-dependent transcription                                         | [41] |
|               | Kaempferol| In vitro    | MCF-7, T47D and MDA-MB-231 cells | –                                                                      | 20–100 µM              | 48 h              | ERK signaling pathway                                                          | [42] |
|               | Kaempferol| In vitro    | MCF-7              | –                                                                      | 10–100 µM              | 24 h              | Inhibition of MCT1-mediated lactate reuptake                                    | [43] |
|               | Kaempferol| In vitro    | MDA-MB-231         | 6 to 8 weeks old male C57BL/6 mice                                   | In vitro: 10–40 µmol/L, In vivo: 50, 100, and 200 mg/kg | 24 h Introgastric administration, daily, 21 days | Inhibition of MAPK signaling pathway                                            | [44] |
|               | Kaempferol| In vitro    | MCF-7              | Female BALB/c nu/nu mice, 6-week-old                                 | In vitro: 50–100 µmol/L, In vivo: 100 mg/kg | 96 h Subcutaneous Injection 2 or 3 times a week for six weeks | ER and IGF-1R signaling pathway                                                | [45] |
Table 1 (continued)

| Cancer types | Treatment | Study | Cell Line | Sample | Dosage | Treatment Period | Mechanisms/Signaling Pathway | Ref |
|--------------|-----------|-------|-----------|--------|--------|-----------------|-------------------------------|-----|
|                  | Kaempferol | In vitro | MCF-7     | –      | 5–700 µM | 48 h            | Downregulation of oct4, nanog, abcb1 and aldha1 | [51] |
|                  | Kaempferol | In vitro | 4T1       | 7 to 8 weeks female BALB/C mice | In vitro: 25 µM/L, In vivo: 40, 80, and 160 mg/kg | 24 h Oral gavage, daily, four weeks | Inhibition of ROS-PAD4 pathway | [52] |
|                  | Kaempferol | In vitro | BT474 and MDA-MB-231 cells | –      | 50 µM/L | 72 h            | Induction of DNA Damage, Promotion of apoptosis | [53] |
|                  | Kaempferol | In vitro | MDA-MB-468 cells | –      | 1–8 nmol paclitaxel and 10–160 µmol/l kaempferol | 24 and 48 h | PI3K/Akt pathway and apoptosis pathway | [134] |
|                  | Kaempferol- verapamil | In vitro | BCSC and MDA-MB-231 cells | 34 tumor samples of patients | 104.8 µM kaempferol and 5 µM verapamil | 48 h | Chemoresistance pathways | [135] |
|                  | Kaempferol-doxorubicin and cisplatin | In vitro | MDA-MB-231 cells | –      | 32, 18 and 9 µg/ml | 24 h | signaling pathways such as apoptosis and angiogenesis | [136] |
| Cervical cancer  | Kaempferol | In vitro | HeLa      | –      | 100 and 200 µM | 48 h | AMP-activated protein kinase-dependent autophagy | [59] |
| Cholangio carcinoma | Kaempferol | In vitro | HCCC9810 and QBC939 | Male BALB/c athymic nude mice (4 weeks old) | In vitro: 30–150 µM, In vivo: 20 mg/kg | 24, 48, 72 h Intraperitoneal injection, daily, Three weeks | Inhibition of PI3K/AKT pathway, apoptosis | [125] |
| Colon cancer    | Kaempferol | In vitro | MSU2, HCT116, KNC | –      | 2.5, 5, 10, and 20 µM | 24 h | Suppression of Jak/Stat3 signaling pathway | [61] |
|                  | Kaempferol | In vitro | HT29, SW480 | –      | 20–60 µM/L | 24 and 48 h | Apoptosis and reduction of Akt activity | [62] |
|                  | Kaempferol | In vitro | RKO and HCT116 | –      | 0.1–1000 µM | 48 h | Upregulation of MMP28 and downregulation of NTRK3 | [63] |
|                  | Kaempferol-TRAIL | In vitro | SW480     | –      | 10–40 µM | 24 h | Apoptosis | [64] |
|                  | Kaempferol-5-fluorouracil | In vitro | HCT8, HCT116 | –      | 100 µM | 24 h |PI3K/Akt signaling pathway | [138] |
|                  | Kaempferol-fluoxetine | In vivo | -         | Adult male Sprague–Dawley rats | 200 mg/kg | Oral administration, daily, 6 weeks | Decreasing ROS production, inhibition of lipid peroxidation | [66] |
| Cancer types          | Treatment                          | Study  | Cell Line                  | Sample                  | Dosage       | Treatment Period | Mechanisms/ Signaling Pathway                                                                 | Ref |
|----------------------|------------------------------------|--------|---------------------------|-------------------------|--------------|------------------|-----------------------------------------------------------------------------------------------|-----|
| Pegylated aups-DOX@ Kaempferol | In Vitro                          | HT-29 cell line | –                          | 50–100 nm              | 48 h         | Intrinsic pathways                                                                                           | [130]|
| Kaempferol-que et cin | In Vitro                          | HT-116 cell line | –                          | 1Q:1 K, 2Q:1 K, and 1Q:2 K | 48 h         | p53-caspase-3 pathway and pro-apoptotic Bcl-2 family members PUMA and Bax                                               | [131]|
| Kaempferol-doxorubcin and cisplatin | In Vitro                          | HCT-15 cells | –                          | 60, 30 and 15 µg/ml    | 24 h         | signaling pathways such as apoptosis and angiogenesis                                                         | [136]|
| Endometrial          | Kaempferol                         | In Vitro | Ishikawa, HEC-265, HEC108, and HEC180 cells | –                      | 36 µM, 72 µM | 48 h             | Suppression of the ER-α and the anti-apoptotic proteins                                                                 | [69]|
|                      | Kaempferol                         | In Vitro | MFE280                     | –                      | 0.5–20 µM    | 24 h             | Inhibition of mTOR/ P3K/Akt signaling pathway                                                                  | [139]|
| Esophageal carcinoma | Kaempferol                         | In Vitro | KYSE150 and Eca109 cells   | Five-week-old female Balb/c athymic nude mice | In vitro: 30–60 µM In vivo: 100 mg/kg | 24, 48, 72 h Intraperitoneal injection, every three days, 25 days | Inhibition of EGFR signaling pathway                                                                 | [122]|
| Fibrosarcoma         | Kaempferol-zinc (II) complex       | In Vitro | EC9706 cells               | –                      | 6, 18, 30 µg/mL | 24 h             | Cellular signaling pathway                                                                                      | [129]|
| Gastric cancer       | Kaempferol                         | In Vitro | HT1080                     | –                      | 10–100 µM    | 24 h             | Blocking NF-kB                                                                                                | [124]|
|                      | Kaempferol                         | In Vitro | MKN28 and SGC7901          | 4-week-old athymic mice | In vitro: 25–200 µM In vivo: 20 mg/kg | 24, 48, 72 h Intraperitoneal injection, daily, 3 weeks | Downregulation of G2/M cell cycle-associated proteins                                              | [72]|
| Head and neck        | Kaempferol                         | In Vitro | AGS, SNU216, NCI-N87, SNU638, and MKN74 | –                      | 25–100 µM    | 8, 16, and 24 h | Induction of autophagic cell                                                                                    | [73]|
|                      | Kaempferol                         | In Vitro | Cal27, HEP2, and DOK      | –                      | 70–280 µM    | 48 and 72 h     | Induction apoptosis and inhibition of the capacity of migration                                                  | [121]|
| Leukemia             | Kaempferol                         | In Vitro | Human monocytic cell line THP1 | –                      | 40 µM        | 12, 24, 48, and 72 h | Significant decrease in Bcl-xL expression                                                                       | [74]|
|                      | Kaempferol                         | In Vitro | CCRF-CEM (CCL1199) and Jurkat E61 (T8152) | –                      | 10 µg/mL     | 4, 12, 24, 48, 72, and 96 h | Production and expression of IL-2 cytokine                                                                  | [140]|
|                      | Kaempferol                         | In Vitro | Human promyelocytic leukemia cell lines, HL60 and NB4 | –                      | 12.5–100 µM  | 24, 48, and 72 h | Decreased viability of leukemia cells                                                                            | [79]|

**Table 1 (continued)**
| Cancer types               | Treatment   | Study       | Cell Line                          | Sample              | Dosage   | Treatment Period | Mechanisms/Signaling Pathway                                                                 | Ref  |
|---------------------------|-------------|-------------|------------------------------------|---------------------|----------|------------------|------------------------------------------------------------------------------------------------|------|
| Liver cancer              | Kaempferol  | In vitro    | Jurkat/Neo cells and Jurkat/Bcl-2 cells | –                   | 25–75 μM | 36 h             | Bak and PUMA upregulation                                                                         | [77] |
|                           | Kaempferol  | In vitro    | MOLT4-cell                         | –                   | 95 μM    | 12, 24, and 48 h | Induced apoptosis                                                                                   | [141]|
|                           | Kaempferol  | In vitro    | Huh7                               | –                   | 0–100 μM | 24 and 48 h      | Inhibition of HIF-1 and MAPK                                                                        | [80] |
|                           | Kaempferol  | In vivo     |                                   | Male wistar albino rats | 100 mg/kg | Oral administration, daily, 28 days | Mitochondrial TCA cycle                                                                             | [81] |
|                           | Kaempferol  | In vitro    | HepG2                              | –                   | 1–20 μM  | 24 h             | Suppression of the downregulatory action of TNF-α                                                   | [82] |
|                           | Kaempferol  | In vitro    | SK-HEP-1                           | –                   | 25–100 μM | 24 h             | Autophagy induction via AMPK, AKT, and mTOR signaling pathways                                      | [83] |
|                           | Kaempferol  | In vitro    | HepG2                              | –                   | 5–100 μM | 3, 6, 12, and 24 h | Activation of ER stress-CHOP pathway                                                               | [85] |
|                           | Kaempferol  | In vitro    | Hepatocytes (obtained from the rat liver of hepatocellular carcinoma) | Male Sprague–Dawley rats | 2.5–100 μM | 24 and 48 h      | Release of cytochrome c via ROS generation before cytotoxicity ensued                               | [86] |
|                           | Kaempferol  | In vitro    | Huh7, Huh1, HepG2, HepG2.2.15, SK- Hep-1, PLC/PRF/5, HLE, HLF, and Hep3B | –                   | 40 μM    | 24, 48, and 72 h | Activating of mitochondrial signaling pathways and inhibition of the PI3K/mTOR/MMP signaling pathway | [89] |
|                           | Kaempferol  | In vitro    | HepG2                              | –                   | 1–20 μM  | 24 h             | Upregulated the ABCA1 mRNA expression                                                              | [84] |
| Lung cancer               | Kaempferol  | In vitro    | A549 and NCIH460                   | –                   | 1–50 μM  | 24, 48, and 72 h | Downregulation of a unique inhibitor of the NF-κB pathway                                           | [90] |
|                           | Kaempferol  | In vitro    | A549                               | –                   | 5–20 μM  | 24 and 48 h      | ERK1/2 signaling pathway                                                                            | [129]|
|                           | Kaempferol  | In vitro    | A549                               | –                   | 17.5–70 μM | 24 and 48 h      | P38/AKT and ERK pathways in cell apoptosis                                                        | [94, 95]|
|                           | Kaempferol  | In vitro    | A549                               | –                   | 10–50 μM | 24 and 48 h      | Activation of MEK-MAPK signaling pathway                                                            | [100]|
| Nervous system cancer     | Kaempferol  | In vitro    | U87 and U251 cells                 | –                   | 50–200 μM | 48 h             | Apoptosis                                                                                          | [101]|

**Table 1** (continued)
| Cancer types          | Treatment          | Study          | Cell Line         | Sample | Dosage          | Treatment Period         | Mechanisms/Signaling Pathway                                                                 | Ref |
|----------------------|-------------------|----------------|-------------------|--------|----------------|--------------------------|---------------------------------------------------------------------------------------------|-----|
| Renal cancer         | Kaempferol        | In vitro       | 786O and 769P     | –      | In vitro: 50–150 μM | 24, 48, 72 h             | Inhibition of MAPK signaling pathways,                                                     | [123]|
| Renal cancer         | Kaempferol        | In vitro       | LNCaP, PC3        | –      | In vitro: 5–15 μM   | 24, 48, 72 h             | Inhibition of cell proliferation via androgen-dependent pathway                              | [113]|
| Pancreatic cancer    | Kaempferol        | In vitro       | Miapaca2, Panc1, and SNU213 cells | –      | 0.005–200 μM     | 72 h                     | Inhibition of EGFR and AKT pathways                                                         | [111]|
|                      |                   | In vitro       | PANC1, Miapaca2 cells | Tumor Xenograft models (male BALB/c mice) | In vitro: 2.5–1000 μmol/L, In vivo: 25–100 mg/kg | 48 h Gavage for seven days | Induction of ROS-dependent apoptosis via Akt/mTOR signaling                                  | [112]|
|                      | Kaempferol-erlotinib | In vitro       | PANC-1 and BxPC-3 cell lines | In vivo: Four-week-old female mice | Various dosages | In vitro: 72 h, In vivo: 4 weeks | PI3K/AKT signaling pathway and epidermal growth factor receptor activation                  | [133]|
| Prostate cancer      | Kaempferol        | In vitro       | PC3               | –      | 10 μM           | 18 h                     | Activation of PLC, PKC, and MEK1/2 cascade                                                  | [22] |
|                      | Kaempferol        | In vitro       | LNCaP, PC3        | –      | 5–15 μM         | 24, 48, 96, and 144 h    | Inhibition of cell proliferation via androgen-dependent pathway                              | [113]|
| Ovarian cancer       | Kaempferol        | In vitro       | OVCAR3 and A2780/CP70 cells | Chick embryo chorioallantoic membrane (CAM) | In vitro: 10–80 μM, In vivo: 20 μM | 24 h Single-dose, five days incubation | Downregulation of HIF-1α, repression of AKT phosphorylation                               | [105]|
|                      |                   | In vivo         | OVCAR3 and A2780/CP70 cells | Chick embryo chorioallantoic membrane (CAM) | In vitro: 10–80 μM, In vivo: 20 μM | 24 h Single-dose, five days incubation | Downregulation of HIF-1α, repression of AKT phosphorylation                               | [105]|
|                      | Kaempferol        | In vitro       | A2780/CP70        | –      | 30–50 μM        | 48 h                     | Caspase-8 pathway                                                                          | [106]|
|                      |                   | In vitro       | Caov3, TOV-112D, SKOV3, OVCAR3 | –      | 12.5–50 μM     | 24 h                     | Upregulation of apoptotic proteins and STAT3 signaling pathways                            | [107]|
|                      | Kaempferol        | In vitro       | A2780             | –      | 40 μmol/l       | 24 h                     | Activation autophagy mechanism                                                             | [108]|
|                      | Kaempferol-cisplatin | In vitro       | A2780             | –      | 40 μmol/l kaempferol with cisplatin (0, 2, 4, 6, 8, 10, 15, 20 μmol/l) | 24 h | PI3K/Akt signalling pathway | |
|                      | Kaempferol-cisplatin | In vitro       | OVCAR-3           | –      | 0–80 μmol/l cisplatin with other chemicals of 0–20 μmol/l | 24 h | Apoptosis caused by down regulation of cMyc | [98]|
|                      | Pancreatic cancer | Kaempferol     | Miapaca2, Panc1, and SNU213 cells | –      | 0.005–200 μM     | 72 h                     | Inhibition of EGFR and AKT pathways                                                         | [111]|
|                      |                   | In vitro       | Miapaca2 cells    | Tumor Xenograft models (male BALB/c mice) | In vitro: 2.5–1000 μmol/L, In vivo: 25–100 mg/kg | 48 h Gavage for seven days | Induction of ROS-dependent apoptosis via Akt/mTOR signaling                                  | [112]|
|                      | Kaempferol-erlotinib | In vitro       | PANC-1 and BxPC-3 cell lines | In vivo: Four-week-old female mice | Various dosages | In vitro: 72 h, In vivo: 4 weeks | PI3K/AKT signaling pathway and epidermal growth factor receptor activation                  | [133]|
|                      |                   | In vivo         | PANC-1 and BxPC-3 cell lines | In vivo: Four-week-old female mice | Various dosages | In vitro: 72 h, In vivo: 4 weeks | PI3K/AKT signaling pathway and epidermal growth factor receptor activation                  | [133]|
|                      |                   | In vitro       | A172              | –      | 50–200 μM       | 6, 12, 24, 36, 48 h       | Induction of cell death                                                                   | [102]|
|                      |                   | In vitro       | PC12              | –      | 5 and 10 μM     | 24 h                     | Inhibiting activation of the NOX-JNK signaling pathway                                     | [103]|
|                      |                   | In vitro       | IMR32 and Neuro2A | –      | 50 μM           | 48, 72, 96 h             | Induction of IRE1a-XBP1 pathway                                                            | [104]|
|                      |                   | In vitro       | Neuro2A           | –      | 50 μM           | 48, 72, 96 h             | Induction of IRE1a-XBP1 pathway                                                            | [104]|
|                      |                   | In vitro       | A2780             | –      | 40 μmol/l       | 24 h                     | PI3K/Akt signalling pathway                                                                | [132]|
|                      |                   | In vitro       | OVCAR3            | –      | 0–80 μmol/l cisplatin with other chemicals of 0–20 μmol/l | 24 h | Apoptosis caused by down regulation of cMyc | [98]|
|                      |                   | In vitro       | A172              | –      | 50–200 μM       | 6, 12, 24, 36, 48 h       | Induction of cell death                                                                   | [102]|
|                      |                   | In vitro       | PC12              | –      | 5 and 10 μM     | 24 h                     | Inhibiting activation of the NOX-JNK signaling pathway                                     | [103]|
|                      |                   | In vitro       | IMR32 and Neuro2A | –      | 50 μM           | 48, 72, 96 h             | Induction of IRE1a-XBP1 pathway                                                            | [104]|
|                      |                   | In vitro       | Neuro2A           | –      | 50 μM           | 48, 72, 96 h             | Induction of IRE1a-XBP1 pathway                                                            | [104]|

**Table 1 (continued)**
Table 1 (continued)

| Cancer types | Treatment                  | Study          | Sample                                                                 | Dosage          | Treatment Period | Mechanisms/ Signaling Pathway                                                                 |
|--------------|----------------------------|----------------|------------------------------------------------------------------------|-----------------|------------------|------------------------------------------------------------------------------------------------|
| Retinoblastoma | Kaempferol                | In vitro       | SO-RB50                                                               | 10–30 μM        | 24 h             | Suppression of Wnt/β-catenin signaling pathway                                                   |
|              |                            |                | 25 human tissue samples (included five normal, 11 normal pediatric retinas, and 14 retinoblastomas) |                 |                  |                                                                                                 |
| Skin cancer  | Kaempferol                | In vitro       | HaCaT                                                                 | 1–10 μM         | 24 h             | PPAR pathways                                                                                   |
|              | Kaempferol                | In vitro       | JB6 P+ mouse epidermal cell line                                       | 10–40 μM        | 24 h             | Inhibition of PI3K activity                                                                      |
|              | Kaempferol                | In vitro       | A431, A431 sh-RSK2, A431 sh-MSK1, or A431 sh-RSK2/sh-MSK1, NIH3T3       | 0–50 μM/L       | 12 weeks         | Topical application, 12 weeks                                                                    |
|              |                            |                | 0.5 or 1 mg                                                           |                 |                  |                                                                                                 |
|              |                            |                | 2 h                                                                   |                 |                  |                                                                                                 |
|              |                            |                | 24 h                                                                  |                 |                  |                                                                                                 |
|              |                            |                | 24, 48, and 72 h                                                      |                 |                  |                                                                                                 |
|              | Kaempferol                | In vitro       | HaCaT                                                                 | 200 µg/mL of Prunus cerasus | 24 h             | Blocking of the mitochondrial pathway of apoptosis                                              |
|              |                            |                |                                                                       |                 |                  |                                                                                                 |
|              | Kaempferol                | In vitro       | A375                                                                 | 10–80 μM        | 24, 48, and 72 h | Induction of apoptosis and downregulation of mTOR/PI3K/AKT pathway                                |

The treatments include kaempferol as a single agent or being combined with erlotinib, cisplatin, zinc, docorubicin, TIM-1, 5-fluourouracil, floxetine, PEGylated AuNPs-DOX, quercetin, paclitaxel, verapamil.

The treatments include kaempferol as a single agent or being combined with erlotinib, cisplatin, zinc, docorubicin, TIM-1, 5-fluourouracil, floxetine, PEGylated AuNPs-DOX, quercetin, paclitaxel, verapamil. Resulted in a more significant antitumor effect and promoted death in colon cancer cells [130].

An investigation presented quercetin and kaempferol's cytotoxic action on HCT-116 cells; some green foods and fruits might contain equivalent amounts of both flavonoids. HCT-116 cells were prevented from entering the G2/M phase of the cell cycle by quercetin and kaempferol's chemopreventive effects, which resulted in a loss of viability in the cells when the two compounds were combined [131]. Chloroquine or sodium phenylbutyrate was added to kaempferol-treated ovarian cancer cells to reverse the effects of kaempferol on ovarian cancer cells (ER stress inhibitor). According to the results of this research, using kaempferol, either alone or in conjunction with cisplatin, may be an effective way to reduce ovarian cell tumorigenesis [132]. PANC-1 and BxPC-3 were inhibited most effectively when kaempferol and erlotinib were used together. An IHC staining confirmed the in vitro results that kaempferol and erlotinib further decreased the expressions of p-EGFR and AKT, as well as p-ERK1/2 and Bax when used together [133]. A critical factor in nanoparticle anti-cancer efficacy is particle size since nanoparticles enter cancer cell walls through increased permeability and retention (EPR). Compared to kaempferol on its own, treating cancer cells with nanoparticles loaded with kaempferol increased early apoptosis by between 0.1 and 6%. The cytotoxicity of paclitaxel was increased when combined with kaempferol-loaded NLCs against MDA-MB-468 murine breast cancer cells [134].

According to a recent study, NANOG, SOX2, MDR1, and CD44 are all induced pluripotent stem cell markers that may be reduced by kaempferol alone or in conjunction with Verapamil. Cancer cells’ survival and acquisition may be slowed by pharmaceutical combinations that interfere with the CD44–NANOG–MDR1 feedback loop activation network, according to a new study [135]. The kaempferol could be effectively conjugated to the AuNCs. The resultant conjugation was selectively harmful to the lung cancer cells while remaining non-toxic to the normal human kidney cells (i.e., HK-2 cell line). The clonogenic experiment provided conclusive evidence that K-AuNCs were responsible for controlling the growth of A549 cells. The findings offer credence to the natural flavonoid kaempferol's potential as an anti-cancer agent in conjunction with AuNCs [98]. The effects of kaempferol are amplified through the downregulation of cMyc, resulting in ovarian cancer cells being more likely to undergo apoptosis due to cisplatin treatment. It was shown that combining kaempferol and cisplatin might synergistically diminish ovarian cancer cells’ vitality. The reduction in cell viability was achieved by blocking the gene transcription of ABCC6 and cMyc [136]. The research presents
the findings of kaempferol-cisplatin-doxorubicin combo investigations. The results demonstrated a substantial synergistic therapeutic benefit when doxorubicin or cisplatin was used in conjunction with kaempferol in HCT-15 and MDA-MB-231 cell lines [137].

As a result, the regulation of complex biological illnesses may be improved by using medication combinations that co-act with one another. In addition to controlling these potential pharmacological actions, kaempferol has also been found to induce other organ protective benefits, as listed in Table 1. Activation of apoptosis and mitochondrial-related pathways and processes has been shown in some studies to be the mechanism by which kaempferol kills cancer cells (Fig. 2).

**Conclusion**

Kaempferol is a bioflavonoid compound involved in reducing the incidence of hormone-related cancers. Oncogene-induced apoptosis and growth inhibition are the primary mechanisms of this compound; however, increasing the host’s immunological response is also considered an important mechanism. When present in more significant quantities, kaempferol is associated with an anti-cancer action; yet, when present in lower concentrations, it is associated with a pro-cancer activity. Kaempferol may have a role in activating apoptosis in many different kinds of cancer cells. If this is the case, kaempferol may have an anti-cancer effect via intrinsic and extrinsic apoptotic pathways. Because of its propensity to limit cell proliferation, kaempferol is engaged in different processes. These activities include activation of JAK/STAT3, PI3K/AKT, and NF-κB, as well as interference with TNF-induced activation of MAPK. Considering the interaction induced by various elements such as gender and immunological conditions is necessary. In vitro and animal studies have been done to determine precisely what function kaempferol plays, but more research is needed to figure out the mechanism(s) by which it works in humans.

In summary, based on the literature that has been published so far, the use of kaempferol in combination therapy is successful. However, there is still a lack of sufficient scientific...
data and regulatory approval from the appropriate authorities. Kaempferol has been shown to have chemotherapeutic potential; however, further data and studies are needed to confirm kaempferol's status as a potentially effective chemotherapeutic drug. Preclinical evidence from human trials must also be obtained before using kaempferol as a chemotherapy drug. And if additional research is done on kaempferol's tumor growth-inhibiting capacity, it might be a valuable therapeutic drug in the future.

Abbreviations
ABC2A1: ATP-binding cassette transporter; ABC6C6: ATP-binding cassette subfamily C member 6; AFB1: Aflatoxin B1; AIF: Apoptosis-inducing factor; AKT: Ak strain transforming; ALPase: Alkaline phosphatase; AHR: Aryl hydrocarbon receptor; AMPK: Adenosine monophosphate activated protein kinase; ATF6: Activating transcription factor 6; ATM: Ataxia telangiectasia mutated; AP-1: Activator protein 1; ATP: Adenosine tri-phosphate; BAX: Bcl-2-associated X protein; Bcl2; B-cell lymphoma 2; GM-CSF: Granulocyte–macrophage colony-stimulating factor; H2AX: H2A histone family member X; HDAC: Histone deacetylase; HIF: Hypoxia-inducible factor; HIF-1α: Heme oxygenase-1; IKK: Nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha; IRE: Insulin-requiring kinase; IRS: Insulin receptor substrate; JAK: Janus kinase; JNK: C-Jun N-terminal kinase; K-AuNCs: Kaempferol-conjugated gold nanoparticles; LC3: Microtubule-associated protein 1A/1B-light chain 3; PERK: Protein kinase RNA-like endoplasmic reticulum kinase; PCR: Polymerase chain reaction; PLC: Phospholipase C; PPAR: Peroxisome proliferator-activated receptor; PTEN: Phosphatase and tensin homolog; PI3K/Akt: Phosphatidylinositol 3-kinase/protein kinase B; PML/RARA: Promyelocytic leukemia/retniculin acid receptor-α; TNF: Tumor necrosis factor; Bcl-xL: B-cell lymphoma-extra large; Bcl-2: B lymphoma domain only death agonist protein; BMI: Body Mass Index; BRCA: Breast cancer type; CAT: Chlorophenolic acid acetyltransferase C; CEBP: CCAAT-enhancer-binding protein β, Cx43: Connexin 43; Caspase: Cysteine-aspartic proteinases, cysteine aspartases; CHOP: CCAAT-enhancer-binding protein homologous protein; c-Met: Metensymchymal epithelial transition factor; CYPIA1: Cytochrome P450, family 1, subfamily A, polypeptide 1; CDK: Cyclin-dependent kinase; CdC25C: A cyclin of the specific phosphatase family that activates the cyclin B1/CDC1 kinase complex; Chk2: The CHEK2 gene encode for checkpoint kinase 2; COX: Cyclooxygenase; MAPK: Mitogen-activated protein kinase; MCF-7: Michigan Cancer Foundation 7; MDR: Multiple drug resistance; MEK: MAPK/ERK kinase; Mfn2: Mitofusin-2; Mcl-1: Myeloid cell leukemia 1; MMPI: Matrix metalloproteinase; MSK: Mitogen and stress-activated kinase; MITT: 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide; mTOR: Mammalian target of rapamycin; NADPH: Reduced nicotinamide adenine dinucleotide phosphate; NAFLD: Nonalcoholic fatty liver disease; PSA: Prostate-specific antigen; RSK: Ribosomal S6 kinase; ROS: Reactive oxygen species; SCD-1: Stearoyl-CoA Desaturase-1; SOD: Superoxide dismutase; SREBP1: Sterol Regulatory Element-Binding Protein-1; Stat3: Signal transducer and activator of transcription 3; TUNEL: Terminal deoxynucleotidyl transferase dUTP nick end labeling; dMDP: Deoxyribo nucleoside Monophosphates; DNMT3B: DNA methyltransferase 3B; EGFR: Epidermal growth factor receptor; ELK1: ETS Transcription factor ELK1; EMT: Epithelial–mesenchymal transition; ERK: Extracellular signal-regulated kinase; ER-negative: Estrogen receptor-negative; ERR: Estrogen-related receptor; ESRR: Estrogen-related receptor alpha; FADD: FAS-associated death domain protein; FRKB2: 12-KDa FK506-binding protein, FGF-8: Fibroblast growth factor 8; GRP78: Glucose Regulated Protein 78,000; GJIC: Gap junction intercellular communication; GLOBOCAN: Global Cancer Incidence, Mortality, and Prevalence; NF-κB: Nuclear factor-kappa-B, NOX: ADP-oxidase; NQO1: NAD(P)H quinone oxidoreductase 1; NQO2: Nuclear factor erythroid 2-related factor 2; PD-2: Protein arginine deiminase 4; PD-1: Programmed cell death protein 1; PD-L1: Programmed death-ligand 1; pAkt: Phosphorylated Protein kinase B; Phox: Phagocyte oxidase; PMA: Phorbol myristate acetate; PKC: Protein kinase C; PARP: Poly (ADP-ribose) polymerase; TCA: Tricarboxylic acid cycle; TFM: Mitochondrial transcription factor A; TGF: Transforming growth factor; TGF2: The transforming growth factor 2 gene; TMP2: Tissue inhibitor of metalloproteinases 2; TMEPA1: Transmembrane prostate androgen protein; TMPRSS2: Transmembrane Serine Protease 2; XIAP: X-linked inhibitor of apoptosis protein; RCC: Renal cell carcinoma.

Acknowledgements
The authors would like to thank the Research Office of Tabriz University of Medical Sciences for providing support under the support scheme (Grant No. 69284).

Author contributions
BS and SA—conceptualization; EA, BS, and SA—data curation; EA and SA—formal analysis; EA and BS—investigation; EA, BS, and SA—methodology; BS—project administration; BS and SA—supervision; EA, BS, and SA—roles/writing—original draft; EA, BS, and SA—writing—review and editing. All authors read and approved the final manuscript.

Funding
Not applicable.

Availability of data and materials
Not applicable.

Declarations
Ethics approval and consent to participate
This article does not contain any studies with human participants or animals performed by any authors.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no conflict of interest.

Received: 21 April 2022 Accepted: 2 August 2022
Published online: 20 August 2022

References
1. Koval S, Murane W, Sasser A, Seiner O, Troth J, Courtine J, Messay B, Jiang A, Guerrero C, Kodali A. Cancer and its treatments. Dartmouth Undergrad J Sci. 2020;1(2021)(Summer):72–87.
2. Cooper G. The cell: a molecular approach. Sunderland: SinauerAssociates; 2000.
3. Migliore L, Coppedè F. Genetic and environmental factors in cancer and neurodegenerative diseases. Mutat Res. 2002;512(2–3):135–53.
4. Yeadon AR, Mohite SK. Cancer—a silent killer. an overview. Asian J Pharm Res. 2020;10(3):213–6.
5. Martin-Moreno JM, Ruiz-Segovia N, Diaz-Rubio E. Behavioural and structural interventions in cancer prevention: towards the 2030 SDG horizon. Mol Oncol. 2021;15(3):801–8.
6. Zhang Y-B, Pan X-F, Chen J, Cao A, Zhang Y-G, Xia L, Wang J, Li H, Liu G, Pan A. Combined lifestyle factors, incident cancer, and cancer mortality: a systematic review and meta-analysis of prospective cohort studies. Br J Cancer. 2020;122(7):1085S–93.
7. Key TJ, Bradbury KE, Perez-Cornaga A, Sinha R, Tsilidis KK, Tsugane S. Diet, nutrition, and cancer risk: what do we know and what is the way forward? BMJ. 2020. https://doi.org/10.1136/bmj.m511.
8. Amjad E, Asnaashari S, Sokouti B, Dastmalchian S. Systems biology comprehensive analysis on breast cancer for identification of key gene modules and genes associated with TNM-based clinical stages. Sci Rep. 2020;10(1):10816.
9. Amjad E, Asnaashari S, Sokouti B, Dastmalchian S. Impact of gene biomarker discovery tools based on protein-protein interaction and machine learning on performance of artificial intelligence models in predicting clinical stages of breast cancer. Interdiscip Sci Comput Life Sci. 2020;12(4):476–86.
10. Saidu R, Morhason-Bello I. Same-day test and treat for early detection and treatment of cervical cancer in LMICs. Lancet Glob Health. S2214-109X(22)003163.
11. Ahmed Md-E, Bhardwaj A. A novel hybrid convolutional neural network approach for the stomach intestinal early detection cancer subtype classification. Comput Intell Neurosci. 2022;1:7325064.

12. Pericleous S, Bhogal RH, Mavroeidis VK. The role of circulating biomarkers in the early detection of recurrent colorectal cancer following resection of liver metastases. Front Biosci-Landmark. 2022;27(6):189.

13. Urruticoechea A, Alemany R, Balart J, Villanueva A, Vinals F, Capella G. Recent advances in cancer therapy: an overview. Curr Pharm Des. 2010;16(1):3–10.

14. Baiker R, Lee KA, Yeo R, Yeoh K-W. Cancer and radiation therapy: current advances and future directions. Int J Med Sci. 2012;9(3):193.

15. Aung TN, Qu Z, Kortschak RD, Adelson DL. Understanding the effectiveness of natural compound mixtures in cancer through their molecular mode of action. Int J Mol Sci. 2017;18(3):656.

16. Housman G, Byler S, Heeboths R, Lapinska K, Longjace M, Snyder N, Sarks S. Drug resistance in cancer: an overview. Cancers (Basel). 2014;6(3):1769–92.

17. Amjadi E, Sokouti B, Asnaashari S. An investigation of 6-Shogao effects on MCF7 cell lines through a systems biology approach. Egypt J Med Genet. 2022;23(1):60.

18. El-Saadony MT, Zabermawi NM, Burollus MA, Shafi ME, Alagawany M, Yehia N, Askar AM, Alasty A, Noreldin AE. Nutritional aspects and health benefits of bioactive plant compounds against infectious diseases: a review. Food Res Int. 2021. https://doi.org/10.1016/j.foodres.2021.1944183.

19. Braicu C, Zanoaga O, Zimta A-A, Tigu AB, Kilpatrick KL, Bishayee A, Braicu C. Differential activity of kaempferol and quercetin in attenuating tumor necrosis factor receptor family signaling in bone cells. Biochim Pharmacol. 2006;71(6):818–26.

20. Calderon-Montano JM, Burgos-Morón E, Pérez-Guerrero C, López-Estepa E, Ibáñez-Salas JP, López-Pérez M, de la Torre J, Rodríguez-Lázaro M. A review on the dietary flavonoid kaempferol. Mini Rev Med Chem. 2011;11(8):294–308.

21. Rascou H, Farzaei MH, Khodarahmi R. Polyphenols and their benefits: a comprehensive review. Molecules. 2020, 25(18):4073.

22. de Vries J, Hollman P, Meyboom S, Buysman M, Zock PL, van Staveren WA, Katan MB. Plasma concentrations and urinary excretion of the antioxidant flavonoids quercetin and kaempferol as biomarkers for dietary intake. Am J Clin Nutr. 2002;41(5):980–8.

23. Oliveir E, Watson D, Grant M. Metabolism of quercetin and kaempferol. Food Res Int. 2015;73:354–9.

24. Crespy V, Morand C, Besson C, Cotelle N, Vézin H, Demigné C, Rémésy C. Oral bioavailability and pharmacokinetics of chemopreventive kaempferol from endive, a source of kaempferol-3-glucuronide, in humans. J Nutr Biochem. 2016;71(6):818–26.

25. Alam W, Khan H, Shah MA, Cauli O, Saso L. Kaempferol as a dietary anti-inflammatory agent: current therapeutic standing. Molecules. 2020;25(18):4073.

26. Li C, Zhao Y, Yang D, Yu Y, Guo H, Zhao Z, Zhang B, Yin X. Inhibitory effects of kaempferol on the invasion of human breast cancer cells by inhibiting ROS-PAD4 pathway. J Cell Mol Med. 2020;24(13):7590–9.

27. Olivera E, Watson D, Grant M. Metabolism of quercetin and kaempferol by rat hepatocytes and the identification of flavonoid glycosides in bile. Drug Metab Dispos. 2006;34(5):980–8.

28. El-Saadony MT, Zabermawi NM, Burollus MA, Shafi ME, Alagawany M, Yehia N, Askar AM, Alasty A, Noreldin AE. Nutritional aspects and health benefits of bioactive plant compounds against infectious diseases: a review. Food Res Int. 2021. https://doi.org/10.1016/j.foodres.2021.1944183.

29. Alam W, Khan H, Shah MA, Cauli O, Saso L. Kaempferol as a dietary anti-inflammatory agent: current therapeutic standing. Molecules. 2020;25(18):4073.

30. Croes A, van der Eijk A, de Vries H, Koster E. The role of circulating biomarkers in the early detection of recurrent colorectal cancer following resection of liver metastases. Front Biosci-Landmark. 2022;27(6):189.

31. Urruticoechea A, Alemany R, Balart J, Villanueva A, Vinals F, Capella G. Recent advances in cancer therapy: an overview. Curr Pharm Des. 2010;16(1):3–10. 11. Ahmed Md-E, Bhardwaj A. A novel hybrid convolutional neural network approach for the stomach intestinal early detection cancer subtype classification. Comput Intell Neurosci. 2022;1:7325064.

12. Pericleous S, Bhogal RH, Mavroeidis VK. The role of circulating biomarkers in the early detection of recurrent colorectal cancer following resection of liver metastases. Front Biosci-Landmark. 2022;27(6):189.

13. Urruticoechea A, Alemany R, Balart J, Villanueva A, Vinals F, Capella G. Recent advances in cancer therapy: an overview. Curr Pharm Des. 2010;16(1):3–10. 11. Ahmed Md-E, Bhardwaj A. A novel hybrid convolutional neural network approach for the stomach intestinal early detection cancer subtype classification. Comput Intell Neurosci. 2022;1:7325064.

12. Pericleous S, Bhogal RH, Mavroeidis VK. The role of circulating biomarkers in the early detection of recurrent colorectal cancer following resection of liver metastases. Front Biosci-Landmark. 2022;27(6):189.
53. Zhu L, Xue L. Kaempferol suppresses proliferation and induces cell cycle arrest, apoptosis, and DNA damage in breast cancer cells. Oncol Res. 2019;27(6):629.

54. Zuo B, Liao ZX, Xu C, Liu C. Two novel prenylated kaempferol derivatives from fresh buds of Quercus acerifolia and their anti-proliferative activities. Nat Prod Res. 2016;30(22):2523–8.

55. Di Infantino A, Subarnas A, Cardaci S, Graziani I, Piccirillo S, Rontolo G, Ciriolo MR. Carcinoma cells activate AMP-activated protein kinase-dependent autophagy as survival response to kaempferol-mediated energetic impairment. Autophagy. 2010;6(2):202–16.

56. Liu J, Xu W, Li C, Wu H, Liu Y. Kaempferol-mediated synthesis of gold nanoparticles and their cytotoxic effects on MCF-7 cancer cell line. Process Biochem. 2018;264:229–40.

57. Nakamura Y, Chang C-C, Mori T, Sato K, Ohtsuki K, Ucham BL, Trosko JE. Augmentation of differentiation and gap junction function by kaempferol in partially differentiated colon cancer cells. Carcinogenesis. 2005;26(5):665–71.

58. Lee HS, Cho HU, Yu R, Lee KW, Chun HS, Park J HY. Mechanisms underlying apoptosis-inducing effects of kaempferol in HT-29 human colon cancer cells. Int J Mol Sci. 2019;15(6):1199.

59. Yoshida T, Konishi M, Horinaka M, Yasuda T, Goda AE, Taniguchi H, Yano K, Wakada M, Sakai T. Kaempferol sensitizes colon cancer cells to TRAIL-induced apoptosis. Biochem Biophys Res Commun. 2003;27(5):67–67.3.

60. Li Q, Wei L, Lin S, Chen Y, Lin J, Peng J. Synergistic effect of kaempferol and S-fluorouracil on the growth of colorectal cancer cells by regulating the PI3K/Akt signalling pathway. Mol Med Rep. 2019;20(1):722–37.

61. Hassain ES, Hassannein NM, Ahmed HMS. Probing the chemoprevention potential of the antidepressant fluoxetine combined with epigallocatechin gallate or kaempferol in rats with induced early stage colon carcinogenesis. J PharmacoSci. 2021;114(5):29–41.

62. Meena D, Vimala K, Kannan S. Combined delivery of DOX and Kaempferol using PEGylated gold nanoparticles to target colon cancer. J Clust Sci. 2021. https://doi.org/10.1007/s10876-021-01996-x.

63. Besso MJ, Montivero L, Lacunza E, Argibay MC, Abba M, Furlong LI, Colas E, Gil-Moreno A, Reventos J, Bello R. Identification of early stage colorectal cancer patients using PEGylated gold nanoparticles and their cytotoxic effects on HepG2 cells. Nanomed. 2012;2(3):S1653–9.

64. Lu W, Du B, Wang T, Wang S, Zhang J. Kaempferol induces apoptosis in human HCT116 colon cancer cells via the Ataxia-Telangiectasia mutated-p53 pathway with the involvement of p53 upregulated modulator of apoptosis. Chem Biol Interact. 2009;177(2):121–7.

65. Moradzadeh M, Tabarzadeh M, Zaefarian HR, Horgan A, Mohamadkhani A, Erfanian S, Sahebkar A. Kaempferol increases apoptosis in human acute promyelocytic leukemia cells and inhibits multidrug resistance genes. J Cell Biochem. 2018;119(2):2288–97.

66. Mylonis I, Lakka A, Tsikalos A, Simos G. The dietary flavonoid kaempferol effectively inhibits HIF-1 activity and hepatoma cancer cell viability under hypoxic conditions. BRBC. 2010;389(1):74–8.

67. Langeswaran K, Revathy R, Kumar SG, Vijayaprakash S, Balasubramanian MP. Kaempferol ameliorates aflatoxin B1 (AFB1) induced hepatocellular carcinoma through modifying metabolizing enzymes, membrane bound ATPases and mitochondrial TCA cycle enzymes. Asian Pac J Trop Biomed. 2012;2(3):5165–9.

68. Li W, Du BY, Zhou Y, Tan YH, Wu YY, Liu JJ, Liu XJ. Effect of kaempferol in inhibiting proliferation and inducing apoptosis of human gastric cancer cell line MGC-803. Zhongguo Zhongdian. 2010;6.

69. Song H, Bao J, Wei Y, Chen Y, Mao X, Li J, Yang Z, Xue Y. Kaempferol inhibits gastric cancer tumor growth: an in vitro and in vivo study. Oncol Rep. 2015;33(2):868–74.

70. Kim TW, Lee SY, Kim M, Cheon C, Ko S-G. Kaempferol induces apiculate cell death via iRE1-JNK-CHOP pathway and inhibition of G9a in gastric cancer cells. Cell Death Dis. 2018;9(9):1–14.

71. Hamid Reza Ghaderi J, Sedigheh S, Abbas Zakeri B. Flavonoids kaempferol (KAE) and quercetin (QUS) inhibited proliferation of human leukemia THP-1 cells by up regulation of pro-apoptotic protein Bax and caspase 3/8 expression and down regulation of anti-apoptotic proteins Bcl-2, Bcl-xl and Mcl-1 expression. Ann Cancer Res Ther. 2021;29(1):141–6.

72. DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH, Konopleva M, Döhner H, Letawi A, Fenaux P, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020;383(7):617–29.

73. Estey E, Karp JE, Emadi A, Othus M, Gale RP. Recent drug approvals for newly diagnosed acute myeloid leukemia: gifts or a Trojan horse? Leukemia. 2020;34(3):671–81.

74. Kim KY, Jang WY, Lee JY, Jun do Y, Ko YH, Yoon YH, Kim YH. Kaempferol activated the cell cycle resulting in G2-arrest and mitochondria-dependent apoptosis in human acute myeloid leukemia Jurkat T cells. J Microbiol Biotechnol. 2016;26(2):287–94.

75. Li W, Du B, Wang T, Wang S, Zhang J. Kaempferol induces apoptosis in human HCT116 colon cancer cells via the Ataxia-Telangiectasia mutated-p53 pathway with the involvement of p53 upregulated modulator of apoptosis. Chem Biol Interact. 2009;177(2):121–7.

76. Moradzadeh M, Tabarzadeh M, Sadehgha HR, Ghorbani A, Mohamadkhani A, Erfanian S, Sahebkar A. Kaempferol increases apoptosis in human acute promyelocytic leukemia cells and inhibits multidrug resistance genes. J Cell Biochem. 2018;119(2):2288–97.

77. Mylonis I, Lakka A, Tsikalos A, Simos G. The dietary flavonoid kaempferol effectively inhibits HIF-1 activity and hepatoma cancer cell viability under hypoxic conditions. BRBC. 2010;389(1):74–8.

78. Langeswaran K, Revathy R, Kumar SG, Vijayaprakash S, Balasubramanian MP. Kaempferol ameliorates aflatoxin B1 (AFB1) induced hepatocellular carcinoma through modifying metabolizing enzymes, membrane bound ATPases and mitochondrial TCA cycle enzymes. Asian Pac J Trop Biomed. 2012;2(3):5165–9.

79. Lu W, Du B, Wang T, Wang S, Zhang J. Kaempferol induces apoptosis in human HCT116 colon cancer cells via the Ataxia-Telangiectasia mutated-p53 pathway with the involvement of p53 upregulated modulator of apoptosis. Chem Biol Interact. 2009;177(2):121–7.

80. Mylonis I, Lakka A, Tsikalos A, Simos G. The dietary flavonoid kaempferol effectively inhibits HIF-1 activity and hepatoma cancer cell viability under hypoxic conditions. BRBC. 2010;389(1):74–8.
91. Siniprasad P, Nair B, Balasubramaniam V, Sadanandan P, Namboori PK, Nath LR. Evaluation of kaempferol as AKT dependent mTOR regulator via targeting FKBP-12 in hepatocellular carcinoma: an in silico approach. Lett Drug Des Discov. 2020;17(11):1401–8.

92. Wang Q, Huang Y, Zhang J-S, Yang X-B. Synthesis, characterization, DNA interaction, and anti-tumor activities of La (III) complex with Schiff base ligand derived from kaempferol and diethylthiurea. Bioorg Chem. 2014;64:219–27.

93. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global Cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.

94. Nguyen TT, Tran E, Ong CK, Lee SK, Do PT, Huynh TT, Nguyen TH, Lee JJ, Kuo WT, Tsai YC, Wu HC, Ho YJ, Chen YS, Yao CH, Yao CH. Radiosensitization of non-small cell lung cancer by kaempferol. Oncol Rep. 2015;33(4):2351–6.

95. Fouzder C, Mukhuty A, Mukherjee S, Malick C, Kundu R. Trigonelline flavonoid kaempferol conjugated gold nanoparticles inhibits Nrf2 via EGFR signalling pathway and augments efficacy of cisplatin and Etoposide in NSCLC cells. Toxicol In Vitro. 2021;70:105038.

96. Govindaraju S, Roshini A, Lee MH, Yun K. Kaempferol inhibits cell proliferation and glycolysis in esophagus squamous cell carcinoma via TGF-α proliferation and glycolysis in esophagus squamous cell carcinoma via TGF-α.

97. Jo E, Park SJ, Choi YS, Jeon WK, Kim BC. Kaempferol suppresses transforming growth factor-β1-induced epithelial-to-mesenchymal transition and migration of A549 lung cancer cells by inhibiting Akt1-mediated phosphorylation of Smad3 at Threonine-179. Neoplasia. 2018;20(7):525–37.

98. Jeong JC, Kim MS, Kim TH, Kim YK. Kaempferol induces cell death through ERK and Akt-dependent down-regulation of XIAP and survivin in human glioma cells. Neurochem Res. 2009;34(5):991–1001.

99. Luo H, Rankin GO, Liu L, Al-Ahmadie YB, Wager D, Yang L, Qin B, Liu J, Liu S, Li B, Ren J. Kaempferol targets estrogen-related receptors in human ovarian carcinoma A2780/CP70 cells. Molecules. 2016;21(38):54–64.

100. Yang J, Xiao P, Sun J, Gao Y, Yin J, Rankin GO, Chen YC. Kaempferol inhibits angiogenesis and VEGF expression through both HIF dependent and independent pathways in human ovarian cancer cells. Nutr Cancer. 2009;61(4):544–53.

101. Gao Y, Yin J, Rankin GO, Chen YC. Kaempferol inhibits angiogenesis and VEGF expression through both HIF dependent and independent pathways in human ovarian cancer cells. Nutr Cancer. 2009;61(4):544–53.

102. Yang S, Li L, Cao X, Zhao T, Jin H, Fang W. Kaempferol inhibits cell proliferation and nuclear factor-κB in human glioma cells. Neurochem Res. 2008;33(8):1338–43.

103. Catalán M, Rodríguez C, Olmedo I, Carrasco-Rojas J, Rojas D, Molina-Berrios A, Díaz-Dosque M, Jara JA. Kaempferol induces cell death and sensitizes human head and neck squamous cell carcinoma cell lines to cisplatin. In: Cell Biology and Translational Medicine, Vol. 12. Cham: Springer; 2020. https://doi.org/10.1007/5584_2020_603

104. Abdullah A, Talwar P, d’Hellencourt CL, Ravanian P. IRE 1α is critical for Kaempferol-induced neuroblastoma differentiation. FEBS J. 2019;286(7):1375–92.

105. Luo H, Rankin GO, Liu L, Daddysman MK, Jiang B-H, Chen YC. Kaempferol inhibits angiogenesis and VEGF expression through both HIF dependent and independent pathways in human ovarian cancer cells. Nutr Cancer. 2009;61(4):544–53.

106. Yang S, Li L, Cao X, Zhao T, Jin H, Fang W. Kaempferol inhibits cell proliferation and nuclear factor-κB in human glioma cells. Neurochem Res. 2008;33(8):1338–43.

107. Yang S, Li L, Cao X, Zhao T, Jin H, Fang W. Kaempferol inhibits cell proliferation and nuclear factor-κB in human glioma cells. Neurochem Res. 2008;33(8):1338–43.
128. Kim JH, Kim YS, Choi J-G, Li W, Lee EJ, Park J-W, Song J, Chung H-S. Kaempferol and its glycoside, kaempferol 7-O-rhamnoside, inhibit PD-1/PD-L1 interaction in vitro. Int J Mol Sci. 2020;21(9):3239.

129. Tu LY, Pi J, Jin H, Cai J-Y, Deng SP. Synthesis, characterization and anticancer activity of kaempferol-zinc(II) complex. Bioorg Med Chem Lett. 2016;26(11):2730–4.

130. Meena D, Vimala K, Kannan S. Combined delivery of DOX and Kaempferol using PEGylated gold nanoparticles to target colon cancer. JCS. 2022;33(1):173–87.

131. Jaramillo Camaroma SM, Lopez S, Abia R, Rodriguez-Arcos R, Jiménez Araujo A, Guillén Bejarano R, Muriana FJ. Combination of quercetin and kaempferol enhances in vitro cytotoxicity on human colon cancer (HCT-116) cells. Rec Nat Prod. 2014;8:262–71.

132. El-Kott AF, Shati AA, Al-Kahtani MA, Alharbi SA. Kaempferol induces cell death in A2780 ovarian cancer cells and increases their sensitivity to cisplatin by activation of cytotoxic endoplasmic reticulum-mediated autophagy and inhibition of protein kinase B. Folia Biol (Praha). 2020;66(1):36–46.

133. Zhang Z, Guo Y, Chen M, Chen F, Liu B, Shen C. Kaempferol potentiates the sensitivity of pancreatic cancer cells to erlotinib via inhibition of the PI3K/AKT signaling pathway and epidermal growth factor receptor. Inflammopharmacology. 2021;29(5):1587–601.

134. Aghazadeh T, Bakhtiar N, Rad IA, Ramezani F. Formulation of kaempferol in nanostructured lipid carriers (NLCs): a delivery platform to sensitization of MDA-MB-468 breast cancer cells to paclitaxel. Biointerface Res Appl Chem. 2021;11(6):14591–601.

135. Nandi SK, Roychowdhury T, Chattopadhyay S, Basu S, Chatterjee K, Choudhury P, Banerjee N, Saha P, Mukhopadhyay S, Mukhopadhyay A, et al. Deregulation of the CD44-NANOG-MDR1 associated chemo resistance pathways of breast cancer stem cells potentiates the anti-cancer effect of Kaempferol in synergism with Verapamil. Toxicol Appl Pharmacol. 2022;437:115887.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.